Its androgen-dependent expression increases in both benign prostate hyperplasia and in prostate carcinoma cells, which both presented high androgen levels [15], while anti-androgen therapy greatly reduces the expression of TRPM8 [16]. Here, TRPM8 is linked to prostate carcinoma.